Skip navigation
Vienna Business Agency
  • Login
  • Deutsch
Vienna Business Agency
  • About us
    • The company
      • Organisation
        • Gender and Diversity
        • Compliance
        • Images
      • Team
  • Funding
    • Programs
    • Online funding application
    • Information
      • Let's talk funding.
  • Consulting
    • Let's talk business.
  • Property
    • Property
    • Technology Centre Seestadt
    • Gewerbehof Seestadt
    • Working space
      • Office space for rent
        • ENERGYbase
        • Mariahilfer Straße
        • Stutterheimstraße
        • Technology Centre Seestadt
      • Labs for rent
      • Office-Services
    • Location development
      • Grätzelinitiative
      • Media Quarter Marx
      • Vienna Biocenter
      • Vienna Business Districts
      • Vienna Innovation Area
  • International Business
    • International Business
    • Business settlement in Vienna
    • Expat in Vienna
  • Startup City Vienna
    • Startup in Vienna
    • Current Calls & Competitions
    • Startup ecosystem
    • FAQs
  • Startup and grow
    • Let's talk founding.
      • Consulting & orientation
      • Coaching
      • Academy workshops
      • Founders Lab
  • Technology
    • Let's talk innovation.
    • Discover technology
      • Workshops for schoolgroups
      • Science Festival 2022
    • Co-Creation Lab Vienna
      • Co-creation lab
  • Creative Industries
    • Developing Vienna's creative industries
    • Mission: creative industries
    • Make things happen
      • Creative Days Vienna
      • Challenges
      • Added value cooperation
    • Competitions
      • Creatives for Vienna
      • Content Vienna
  • News, Workshops and Events
    • News
    • Events
    • Academy-Workshops
  • Viennese stories
    • Overview
    • #viennagoeson
      • Goldsmith Avalone
      • Compact Electric
      • FATEEVA
      • Ferrari Zöchling
      • House of SUPERSENSE
      • Innenhofstudios
      • Media Apparat
      • Silvia Müller
      • Vanillas
      • feinedinge*
      • Glein
    • Urban Food
      • blün
      • Fleischerei Klaghofer
      • iss mich!
      • Kasnudl
      • markta and unverschwendet
      • Viennese Obstraupe
      • Revo Foods
      • Vollpension
      • Wiegert
    • Life Sciences
      • Apeiron
      • G.ST Antivirals
      • One of the largest axolotl colonies in the world lives at the Vienna BioCenter
      • Marinomed
      • mySugr
      • PreGenerate
    • Attraktion!
    • Mate Matcher
    • Pocket Cocktails
    • Bookshop Seeseiten
    • Scissor, stone, paper from vienna

Apeiron

Keeping cancer in check

Hans Loibner is the CEO at Viennese biotech company Apeiron Biologics. In an interview, the qualified chemist speaks about Apeiron’s latest achievements in cancer therapy and Vienna’s merits as a location for the life sciences and biotech industry.

  • In your opinion, what are the benefits of Vienna as a location for life sciences?

Hans Loibner: Vienna is a great city. That, in itself, is already a key factor for people from overseas who have decided to come here. What’s more, Vienna has an above-average number of good funding measures on offer, especially for startups.

  • It seems that Vienna’s life sciences branch is flourishing especially well, at the moment. In fact, Vienna has already been successfully involved in the biotech industry for several decades. What is your view of current developments?

After two decades in research and development at a large pharmaceuticals company in Vienna, I have been working on the Viennese life sciences scene since 1999, and somehow, I have been able to accompany and play my part in its design from the early days. The biotech business is especially one of the riskiest entrepreneurial activities that exists, and also often experiences setbacks. It is actually “normal” for modern and new kinds of therapy developments to be frequently unsuccessful. This also explains the coming and going of biotech companies in Vienna, and, in fact, also across the world.

  • What, then, has changed in Vienna as well as the industry in the past ten years?

Overall, the Viennese scene is impressive. I also believe more companies are founded than before - thanks to the support of good initial funding measures by the city and the government, as well as from investors that are prepared to take on the risks. In my opinion, what is most important, however, are the entrepreneurs and suitable employees. It is lovely to see such a positive development here.

  • What was behind Apeiron’s decision to move to Vienna?

Apeiron was founded by Professor Penninger at the end of 2003. At the time, he was one of the leading Austrian geneticists working in Vienna again. For him, Vienna was simply an obvious location choice.

  • You yourself joined Apeiron in 2005?

That’s right. I then built up the company from 2005 onwards – and I myself was born in Vienna and am very interested in internationalisation.

  • How crucial is the issue of location for your company?

Of course, Apeiron could also choose to base their operations in, for example, San Diego. If nothing else, it would offer a great perspective for me personally, as I am not so fond of winter in Vienna. In principle, you can really move a company anywhere, but most of the people who actually make it what it is would not come along.

  • In the Vienna Biocenter, the Vienna Business Agency is establishing more than 70 flexible startup labs on an area of over 1,000m², with these available from 2019 onwards. What impulses do you expect this will have on the industry as a whole? How important are startups in the life sciences branch?

That’s simple: every impulse for startups is important for the branch because startups are essential for a successful life sciences scene.

  • The medication dinutuximab beta developed by Apeiron to combat neuroblastoma – one of the most common malignant tumour diseases among children – was approved for treatment by the EU authorities in the past year. How significant is this achievement for your company and for neuroblastoma therapy itself?

The market approval in the European Union is currently the greatest accomplishment in the history of Apeiron. In recent years, only a few biotech companies of a similar size, or small size, across Europe have gained market approval for a product in the EU by their own efforts. However, the significance for neuroblastoma patients and their families is far more important than this company-strategic, and of course, commercial accomplishment: dinutuximab beta now represents the only immunotherapy for high-risk neuroblastoma currently available in Europe. The product improves the results from the treatment of this very serious, early-childhood cancer substantially and in the long term.

  • What do you believe are the greatest challenges in pharmaceutical development?

We could make a very long list for that. Pharmaceutical development is one of the most complex things that humans have ever come up with. To name two key challenges: the first challenge is that the product hoped for or designed actually has a sufficient, medically useful effect. Unfortunately, this is often discovered very late on, after years of work and the use of vast resources. Another difficulty is overcoming the unbelievably many hurdles or regulations that humanity itself has set – although with the good intention of protecting patients. However, these framework conditions impede, slow down and increase the price of already complex developments and in my opinion, are ethically problematic, for example, when it’s about the fight against life-threatening diseases such as cancer.

  • Currently, your company is developing, among other things, a new, special immunotherapy against cancer. How elaborate is this research and what results are you expecting?

Every new innovative research and especially, development, is complex and challenging, as you are constantly breaking new ground. Our APN401 immunotherapy is unique in the world. This means that we cannot orientate ourselves around anything. Most of our steps are a combination of boldness, innovation and risk. An exciting challenge. We wouldn’t do it if we weren’t expecting excellent results: helping the immune system to activate itself against many kinds and stages of cancer so that it can keep these diseases in check, and without having greater side effects in the process.

  • If you dared to glance into the future: what do you believe cancer therapy will look like in the year 2050?

2050 will probably be after my time, but perhaps I have helped it on a bit farther: in the future, cancer therapy will be less of a therapy AGAINST cancer, but rather one FOR the immune system. To me, the immune system is the key to conquering this complex phenomenon that we simply call cancer.

Services/grants provided by the Vienna Business Agency:

  • Grants received through call "BEFOR Call 2003"
  • Grants received through call "CoOperateEnlarged 2008"
  • Grants received through call "Patients in Focus 2009"
  • Grants received through call "TRANSKOOP WIEN"
  • Grants received through call "FemPower 2012"

Company Contact:

APEIRON Biologics AG
Campus-Vienna-Biocenter 5
1030 Wien

https://www.apeiron-biologics.com/

  • Contact
  • Newsletter
  • Jobs
  • Press
  • Imprint
  • Data protection

Vienna Business Agency.
A service offered by the
City of Vienna.

Mariahilfer Straße 20 1070 Vienna Austria

+43 1 25200

  • Facebook
  • LinkedIn

Cookies

We are constantly working to improve our services. We use cookies to tailor our content to your needs as best as possible.

Data protection

Analysis

no
yes
Google Analytics
no
yes
Google Ireland Limited Show details Hide details

Purpose: technical enablement for the use of analysis tools
Processing operations: no collection of personal data
Storage duration: -
Joint controller: Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland
Legal basis for data processing: voluntary, revocable consent at any time
Consequences of non-consent: No direct effect on the function of the website; However, limited possibilities for further development and error analysis

Marketing

no
yes
Facebook Pixel
no
yes
Facebook Ireland Ltd. Show details Hide details

Purpose: error analysis, statistical evaluation of our website access, campaign analysis, conversion tracking, retargeting
Processing operations:
Http headers – contain IP addresses, web browser information, page location, document, referrer and website visitor.
Pixel-specific data - e.g. the pixel ID and the Facebook cookie.
Button Click Data - Labels and any pages viewed as a result of clicking the button.
Optional Values ​​– Developers and marketers can optionally send additional visit information via personalized data events. Examples of personalized data events include conversion value, page type, and more.
Form Field Names - This includes the names of website fields such as email, address, and quantity.
Storage period: Facebook stores data until it is no longer needed or until your Facebook account is deleted, whichever comes first.
Joint controller: Facebook Ireland Ltd., 4 Grand Canal Square, Grand Canal Harbour, Dublin 2 Ireland
Legal basis for data processing: voluntary, revocable consent at any time
Consequences of non-consent: No direct effect on the function of the website; However, limited possibilities for further development and error analysis
Data transmission to the USA: Your data will be processed by the provider Facebook in the USA, which involves corresponding risks, e.g. B. secret data access by US authorities. With your consent, you also agree to the processing of your data in the USA.